Overview

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn how to identify early which patients will respond to chemotherapy plus radiation therapy in order to reduce the number of subjects who require surgery (followed by radiation therapy).
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center
University of Michigan Rogel Cancer Center
Treatments:
Cetuximab
Cisplatin
Docetaxel
Fluorouracil